dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Nikolaides, C. | en |
dc.contributor.author | Athanasiades, A. | en |
dc.contributor.author | Beriatou, K. | en |
dc.contributor.author | Skarlos, Dimosthenis V. | en |
dc.contributor.author | Giannakakis, T. | en |
dc.contributor.author | Kosmidis, Paraskevas A. | en |
dc.contributor.author | Karvounis, N. | en |
dc.contributor.author | Fountzilas, George | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Nikolaides, C. | en |
dc.creator | Athanasiades, A. | en |
dc.creator | Beriatou, K. | en |
dc.creator | Skarlos, Dimosthenis V. | en |
dc.creator | Giannakakis, T. | en |
dc.creator | Kosmidis, Paraskevas A. | en |
dc.creator | Karvounis, N. | en |
dc.creator | Fountzilas, George | en |
dc.date.accessioned | 2018-06-22T09:54:20Z | |
dc.date.available | 2018-06-22T09:54:20Z | |
dc.date.issued | 1996 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42310 | |
dc.description.abstract | Preclinical data have shown a synergism between 5-fluorouracil and interferon-γ against human colon carcinoma cell lines. We conducted a phase II trial of this combination in 34 patients with metastatic colorectal cancer. 5-Fluorouracil was administered as an intravenous bolus of 500 mg/m2 weekly and interferon-γ subcutaneous injection at a dose of 200 μg (6 × 106 IU) 3 times a week. Thirty-two patients were evaluable for response. There was one complete and two partial responses (response rate 9.0%, 95% CI 1.98–25.02%). Eleven patients (34%) had stable disease. Common toxicities included fever 81%, nausea/vomiting 19%, diarrhea 16%, flu-like syndrome 16%, malaise 12.5% and leukopenia 12.5%. These results indicate that the above combination of 5-fiuorouracil and interferon-γ has an unimpressive activity in patients with advanced colorectal carcinoma. Toxicity was very tolerable. © 1996 S. Karger AG, Basel. | en |
dc.language.iso | eng | en |
dc.source | Oncology (Switzerland) | en |
dc.subject | Interferon-γ | el |
dc.subject | Article | en |
dc.subject | Antineoplastic agent | en |
dc.subject | Fluorouracil | en |
dc.subject | Human | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Female | en |
dc.subject | Middle aged | en |
dc.subject | Cancer combination chemotherapy | en |
dc.subject | Priority journal | en |
dc.subject | Anemia | en |
dc.subject | Antineoplastic combined chemotherapy protocols | en |
dc.subject | Clinical article | en |
dc.subject | Clinical trial | en |
dc.subject | Diarrhea | en |
dc.subject | Leukopenia | en |
dc.subject | Neutropenia | en |
dc.subject | Phase 2 clinical trial | en |
dc.subject | Prospective studies | en |
dc.subject | Thrombocytopenia | en |
dc.subject | Treatment outcome | en |
dc.subject | Antineoplastic activity | en |
dc.subject | Fever | en |
dc.subject | Metastasis | en |
dc.subject | Neoplasm metastasis | en |
dc.subject | Colorectal cancer | en |
dc.subject | Gamma interferon | en |
dc.subject | Interferon type ii | en |
dc.subject | Malaise | en |
dc.subject | Male | en |
dc.subject | Intravenous drug administration | en |
dc.subject | Subcutaneous drug administration | en |
dc.subject | Vomiting | en |
dc.subject | Colorectal neoplasms | en |
dc.subject | Drug tolerance | en |
dc.subject | Nausea | en |
dc.subject | 5-fluorouracil | en |
dc.subject | Influenza | en |
dc.subject | Colorectal carcinoma advanced | en |
dc.subject | Dry skin | en |
dc.title | Phase II Study of 5-Fluorouracil and Interferon-Gamma in Patients with Metastatic Colorectal Cancer | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1159/000227553 | |
dc.description.volume | 53 | |
dc.description.issue | 2 | |
dc.description.startingpage | 159 | |
dc.description.endingpage | 162 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |